Skip to content

Study · Not a test of the peptide alone · 2018

4 results

Subtyping of primary aldosteronism with adrenal vein sampling: Hormone- and side-specific effects of cosyntropin and metoclopramide.

Rossitto G, Maiolino G, Lenzini L, Bisogni V, Seccia TM, Cesari M, Iacobone M, Rossi GP

Surgery1 Dec 2017Cited by 26 (Europe PMC)

PMID29198769 (opens in a new tab)DOI10.1016/j.surg.2017.09.032 (opens in a new tab)PepBankPUB-29198769
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cosyntropin.

  1. 01HumanNot a test of Cosyntropin aloneNon-randomized trialOther

    In primary aldosteronism patients, cosyntropin increased the selectivity index similarly on both sides.

    In plain wordsIn primary aldosteronism patients, cosyntropin increased the selectivity index on both sides versus baseline.

    Peptide
    Cosyntropin
    Outcome
    IncreaseSelectivity index
    Study

    n = 53

    Comparator
    Before cosyntropin
    Outcome group
    Diagnostic test performance · Endocrine and hormones

    Source sentences

    Summary
    Cosyntropin increased the selectivity index similarly on both sides; metoclopramide did not.
    1 context sentence
    Summary · context
    We recruited 171 patients; of these, 149 underwent adrenal vein sampling before and after stimulation with cosyntropin (250 µg intravenous bolus, n= 53, 73% with an aldosterone-producing adenoma)

    In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.

  2. 02HumanNot a test of Cosyntropin aloneNon-randomized trialOther

    In primary aldosteronism patients, cosyntropin did not decrease relative aldosterone secretion index contralaterally.

    In plain wordsIn primary aldosteronism patients, cosyntropin did not lower the opposite-side secretion index versus baseline.

    Peptide
    Cosyntropin
    Outcome
    No significant changeContralateral relative aldosterone secretion index
    Study

    n = 53

    Comparator
    Before cosyntropin
    Outcome group
    Diagnostic test performance · Endocrine and hormones

    Source sentences

    Summary
    Cosyntropin decreased relative aldosterone secretion index on the aldosterone-producing adenoma side but not contralaterally.
    1 context sentence
    Summary · context
    We recruited 171 patients; of these, 149 underwent adrenal vein sampling before and after stimulation with cosyntropin (250 µg intravenous bolus, n= 53, 73% with an aldosterone-producing adenoma)

    In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.

  3. 03HumanNot a test of Cosyntropin aloneNon-randomized trialOther

    In primary aldosteronism patients, cosyntropin decreased the lateralization index.

    In plain wordsIn primary aldosteronism patients, cosyntropin lowered the lateralization index versus baseline.

    Peptide
    Cosyntropin
    Outcome
    DecreaseLateralization index
    Study

    n = 53

    Comparator
    Before cosyntropin
    Outcome group
    Diagnostic test performance · Endocrine and hormones

    Source sentences

    Summary
    Because of these changes, cosyntropin decreased the lateralization index, while metoclopramide did not affect it.
    1 context sentence
    Summary · context
    We recruited 171 patients; of these, 149 underwent adrenal vein sampling before and after stimulation with cosyntropin (250 µg intravenous bolus, n= 53, 73% with an aldosterone-producing adenoma)

    In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.

  4. 04HumanNot a test of Cosyntropin aloneNon-randomized trialOther

    In primary aldosteronism patients, cosyntropin decreased the relative aldosterone secretion index on the adenoma side but not contralaterally.

    In plain wordsIn primary aldosteronism patients, cosyntropin lowered the adenoma-side secretion index versus baseline but not on the opposite side.

    Peptide
    Cosyntropin
    Outcome
    DecreaseAdenoma-side relative aldosterone secretion index
    Study

    n: not reported in source

    Comparator
    Before cosyntropin
    Outcome group
    Diagnostic test performance · Endocrine and hormones

    Source sentences

    Summary
    Cosyntropin decreased relative aldosterone secretion index on the aldosterone-producing adenoma side but not contralaterally.
    1 context sentence
    Summary · context
    We recruited 171 patients; of these, 149 underwent adrenal vein sampling before and after stimulation with cosyntropin (250 µg intravenous bolus, n= 53, 73% with an aldosterone-producing adenoma)

    In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.